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Abstract
Thienopyridine derivatives such as clopidogrel have been shown to reduce the incidence of death in
patients undergoing percutaneous coronary intervention when used in conjunction with aspirin.
Recently, a new thienopyridine, prasugrel, significantly reduced the primary endpoint of
cardiovascular death, non-fatal myocardial infarction or non-fatal stroke to 9.9% compared to
12.1% for clopidogrel. Prasugrel has been shown to be more efficacious than clopidigrel in reducing
ischemic events and stent thrombosis, but does cause more life-threatening bleeding in patients
undergoing percutaneous coronary intervention.
Introduction and context
Aspirin reduces the aggregation of platelets exposed to
thrombogenic stimuli by inhibiting the cyclo-oxygenase
enzyme reaction within the platelet, thereby blocking the
conversion of arachidonic acid to thromboxane A2.
Clopidogrel and ticlopidine are thienopyridine deriva-
tives that inhibit platelet aggregation by inhibiting the
binding of adenosine 5'-diphosphate (ADP) to its
platelet receptor.
The final common pathway of platelet aggregation is
mediated by activation of platelet glycoprotein IIb/IIIa
receptors by a platelet agonist such as ADP, collagen, or
thrombin followed by cross-linking of activated recep-
tors by circulating fibrinogen molecules. Although
intravenous platelet glycoprotein IIb/IIIa inhibitors are
effective in treating patients with acute coronary syn-
dromes undergoing percutaneous coronary intervention
(PCI), especially in diabetics [1], oral platelet glycopro-
tein IIb/IIIa inhibitors have been found to increase
mortality [2].
In the Clopidogrel in Unstable Angina to Prevent
Recurrent Events (CURE) trial, 2658 patients, mean age
62 ± 11 years, underwent PCI [3]. The primary endpoint
of cardiovascular death, myocardial infarction (MI), or
urgent target vessel revascularization within 30 days of
PCI was significantly reduced from 6.4% in patients
treated with aspirin plus placebo to 4.5% in patients
treated with aspirin plus clopidogrel (loading dose
300 mg and maintenance dose 75 mg daily), a relative
risk reduction of 30% and an absolute risk reduction of
1.9% [number needed to treat (NNT) 53 persons] with
no significant difference in major bleeding between the
two groups. At 8-month follow-up, clopidogrel plus
aspirin significantly reduced cardiovascular death or MI
by 31%, from 12.6 to 8.8% (NNT 26 persons). These
data are from a post-randomization analysis.
In the Clopidogrel for the Reduction of Events During
Observation (CREDO) trial, 2116 patients, mean age
62 ± 11 years, undergoing elective PCI or deemed at high
likelihood of undergoing PCI, were randomized to
aspirin plus clopidogrel (loading dose 300 mg and
maintenance dose 75 mg daily) or to aspirin plus
placebo for 12 months [4]. At 1-year follow-up,
clopidogrel significantly reduced the incidence of
death, MI, and stroke from 11.5 to 8.5%, with a relative
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3.0% caused by clopidogrel (NNT 33 persons).
The current American College of Cardiology/American
Heart Association guidelines for PCI recommend the use
of aspirin and clopidogrel (loading dose of 300 mg
followed by a maintenance dose of 75 mg daily) at the
time of PCI, followed by 75 to 162 mg of aspirin daily
continuing indefinitely after PCI. The guidelines also
recommend 75 mg of clopidogrel daily for at least
1 month after bare-metal stent implantation, for at least
3 months after sirolimus stent implantation, for at least
6 months after paclitaxel stent implantation, and ideally
for at least 1 year in patients not at high risk of bleeding
[5]. Intravenous platelet glycoprotein IIb/IIIa inhibitors
may be used at the time of PCI [5]. Of our last 1000
patients who had PCI, 100% were treated with aspirin,
100% with clopidogrel (usually with a loading dose of
600 mg daily), and 13% with intravenous platelet
glycoprotein IIb/IIIa inhibitors.
Recent advances
Prasugrel is a new thienopyridine that inhibits ADP-
induced aggregation more consistently, and to a greater
extent, than standard and higher doses of clopidogrel in
patients undergoing PCI [6]. In the Trial to Assess
Improvement in Therapeutic Outcomes by Optimizing
Platelet Inhibition with Prasugrel-Thrombolysis in Myo-
cardial Infarction (TRITON-TIMI) 38, 13,608 patients
with moderate- to high-risk acute coronary syndromes
with scheduled PCI treated with aspirin were rando-
mized to prasugrel (loading dose of 60 mg followed by a
maintenance dose of 10 mg daily) or to clopidogrel
(loading dose of 300 mg followed by a maintenance
dose of 75 mg daily) [7]. At 14.5-month median follow-
up, the primary endpoint of cardiovascular death, non-
fatal MI, or non-fatal stroke was significantly reduced to
9.9% in those randomized to prasugrel, compared to
12.1% in those treated with clopidogrel (absolute risk
reduction 2.2%; relative risk reduction 19%; P < 0.001;
NNT 45 persons). Life-threatening bleeding occurred in
1.4% of patients receiving prasugrel versus 0.9% receiv-
ing clopidogrel (hazard ratio = 1.52, P = 0.01).
Stent thrombosis was significantly reduced by prasugrel
in patients with drug-eluting stents by 64% (from 2.31 to
0.84%), and by 48% in patients with bare-metal stents
(from 2.41 to 1.27%) [8]. These data are difficult to
interpret since the use of bare-metal stents and of drug-
eluting stents was not randomized. The overall reduction
in stent thrombosis by prasugrel was 52% (from 2.35%
in patients receiving clopidogrel to 1.13% in those
receiving prasugrel). When events that occurred while
patients had been off the study drug for longer than
7 days were excluded, a 55% decrease in stent
thrombosis in favor of prasugrel was found (0.98%
versus 2.14%; hazard ratio = 0.45; P < 0.0001).
Among patients with a history of stroke or transient
ischemic attack, intracranial hemorrhage was increased
from 0% on clopidogrel to 2.3% on prasugrel (P = 0.02)
[7]. Patients aged 75 years and older and patients with a
body weight less than 60 kg had a similar incidence of
cardiovascular death, non-fatal MI, or non-fatal stroke if
they were treated with prasugrel (16.1%) or clopidogrel
(16.0%), but a 42% insignificant increase in major
bleeding related to non-coronary artery bypass grafting-
related non-fatal thrombolysis in MI on prasugrel
(4.3%), compared to clopidogrel (3.3%) [7]. These
data were identified post hoc.
Implications for clinical practice
On the basis of the available data, prasugrel is more
efficacious than clopidogrel in reducing ischemic events
and stent thrombosis but causes more life-threatening
major bleeding than clopidogrel in patients undergoing
PCI. Clinical judgment needs to be used in determining
which antiplatelet drug to use if prasugrel is approved by
regulatory agencies. Younger persons at high risk for
ischemic events with no comorbidities and a low risk for
major bleeding would benefit from the use of a more
potent antiplatelet drug, such as prasugrel. However, I
would use clopidogrel rather than prasugrel in patients
with a history of stroke or transient ischemic attack, in
patients aged 75 years and older, in patients with a body
weight less than 60 kg, and in patients at high risk for
bleeding, such as those with comorbidities like signifi-
cant renal dysfunction.
Abbreviations
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